Manufacturers think CMS bars them from helping #Medicare patients afford their medicines. This is incorrect. Join the RE webinar to understand how patient services can help ensure affordable access for Medicare Beneficiaries. #marketaccess Register: bit.ly/39QcqVW

Our CEO, @Berkowij joined @jimbojoyce and @HealthEugene for their podcast #TheShot of #DigitalHealth. Listen for a discussion on the early days of pharma market access, digital therapeutics, & #RealEndpoints revolutionary approach to VBAs. Watch here: bit.ly/373RtWm

Options, Expertise and Risk Tolerance say it all! The Real Endpoints Marketplace for #ValueBasedContracting addresses all of these. Contact us for expert support in developing and placing these arrangements. Read on our LinkedIn: bit.ly/2KUN1B8

Big approvals are starting in 2021.In a competitive heart failure market,will Verquvo be able to avoid market access challenges of products like Entresto (payer management,provider/patient access)Payers,providers,time will tell:bit.ly/3bY4JPh

With nearly 400 gene cell therapy candidates in clinical trials,FDA anticipating approving up to 20 gene cell therapies annually by 2025-pricing/market access will be a major focus.RE has expertise in tackling the road to reimbursement. bit.ly/2X4rLvc

ICER's just released Unsupported Drug Price Increase Report is bound to stir controversy in trying to determine whether new clinical evidence supports "substantial" price increases for drugs with a large impact on U.S. drug spending. Interesting reading - icer.org/wp-content/uploads/…

2021 drug price increases are coming in at 3.3% on average, exceeding the 1.2% 2020 inflation rate. Will the ability to take drug price increases survive a new administration? Read here: bit.ly/2MAxEyd

Our CCO, Dr Barlow, offers a valuable playbook for securing sustainable reimbursement for innovative gene therapies in this article. Payers will continue to seek & implement solutions to address the challenges of one-time high cost gene therapy treatments. bit.ly/2Mx1cNf

The Real Endpoints team thanks all of our colleagues, clients and friends for pulling together this year. We wish you and your families a safe and happy holiday. Looking forward to the sun coming out on a new year - one filled with good health and good fortune.

Finally! The CMS Final Rule revising average manufacture price & "best price" reporting requirements will be a potential game-changer paving the way for a new generation of innovative contracting methodologies based on value. bit.ly/34zrfty #valuebasedpricing #cms

Announcing a win-win-win solution for patients, biopharmas, and payers wrestling with the challenges of rare-disease drug access: RE #Marketplace linkedin.com/posts/real-endp…

Real Endpoints is thrilled to welcome Rob O'Brien to our team. Rob's deep expertise in #specialtypharmacy & over two decades with the largest #PBM in the country will provide immeasurable value to our clients. Welcome aboard Rob! globenewswire.com/fr/news-re… #pharmaceuticals #pricing

Real Endpoints President @Swraiola05 was honored to participate in an important panel discussion on cancer care and the benefits of HUB support services models during the 2020 Association Value Based Cancer Care Summit. #AVBCC2020 #cancercare #hubservices

Value-based deals will be an essential part of the future of contracting but none have yet publicly shared the results. RE introduced them, helped structure & manage the analytics of the deal with these these partners @HarvardPilgrim & @Illumina. Listen in:bit.ly/2HupwNP

#ICER ‘s influence has increased dramatically with the launch of its interactive modeler-so has it’s financial stability.Thanks to what looks like a new subscription-based business model,it might be able to free itself from its risky dependence on donors. lnkd.in/gEQXxZM

Agree with #ICER or not, interesting White Paper on the complex state of play in cost-sharing, formulary development and prior authorizations. Speaks to the continued disconnect between coverage and #reimbursement and patient affordability. Read here: bit.ly/3nC6lBP

It's that time of year when the large PBM’s including #cvshealth, publish their FORMULARY EXCLUSION lists. More than 200 #drugs have been excluded going into 2021. Surprised by any drug listed for removal? bit.ly/3iEUnnd @RealEndptsRog @Berkowij @NashBeth @NazoAhmed

Uptake of value based contracts is pivoting from chronic use drugs to high-cost agents like cell & #GeneTherapy. #realendpoints is introducing a platform for working with manufacturers & Payors on these types of arrangements. Contact us for an overview. bit.ly/33BWCDF

Real Endpoints CEO, @Berkowij just participated in a robust discussion of market access & the evolution of customer facing teams at the @indegeneinsight #DigitalSummit with panelists Kent Rogers Dana Rodden & others.Register to hear more insights: lnkd.in/dcMqS-9 #IDS2020